- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05277922
Effect of C21 on Forearm Blood Flow
November 11, 2022 updated by: Vicore Pharma AB
A Phase 1, Open-label, Single-centre Study Investigating the Effect of C21 on Forearm Blood Flow in Healthy Male Subjects by Use of Strain-gauge Venous Occlusion Plethysmography
The purpose of this study is to assess the effect of C21 on forearm blood flow by use of strain-gauge venous occlusion plethysmography.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Subject will be screened for eligibility. Eligible subjects will receive ascending doses of C21 (3, 10, 30 and 100 µg/min through locla i.a. infusions for 5 min/dose. Forearm blood flow measurements will be performed in both arms during the last 2 minutes of each dose.
infusions of sodium nitroprusside will be performed as a positive control using the same methodology.
Study Type
Interventional
Enrollment (Actual)
5
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Uppsala Lân
-
Uppsala, Uppsala Lân, Sweden, 75237
- Clinical Trial Consultants AB
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Willing and able to give written informed consent for participation in the study and to comply with study requirements.
- Healthy male subject aged 18-45 years
- Body mass index ≥ 18.5 and ≤ 30.0 kg/m2.
- Wlling to use condom or be vasectomised or practice sexual abstinence
- Clinically normal medical history, physical findings, vital signs, ECG and laboratory values
Exclusion Criteria:
- History of any clinically significant disease or disorder which may either put the subject at risk because of participation in the study, or influence the results or the subject's ability to participate in the study.
- History of thrombotic disease, vascular disorder, or severe bleeding disease.
- Poor brachial artery access.
- Any clinically significant illness, medical/surgical procedure, or trauma within 4 weeks of baseline
- Malignancy within the past 5 years with the exception of basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years.
- Any planned major surgery within the duration of the study.
- Any positive result on screening for serum hepatitis B surface antigen, hepatitis C antibody and human immunodeficiency virus (HIV).
- Abnormal vital signs
- Prolonged QT interval, cardiac arrhythmias or any clinically significant abnormalities in the resting ECG
- History of severe allergy/hypersensitivity or ongoing allergy/hypersensitivity or history of hypersensitivity to drugs with a similar chemical structure or class to the IMPs, including any of the excipients of the IMPs.
- Regular use of any prescribed or non-prescribed medication including antacids, analgesics, herbal remedies, vitamins, and minerals
- Regular use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid
- Vaccination within 1 week prior to dosing or plans to receive any vaccine during the study conduct.
- Planned treatment or treatment with another investigational drug within 3 months
- Current regular smokers or users of nicotine products.
- History of alcohol abuse
- Presence or history of drug abuse
- Positive screen for drugs of abuse or alcohol at screening
- History of, or current use of, anabolic steroids.
- Inability to refrain from consuming caffeine-containing beverages during Day 1
- Plasma donation within 1 month of screening or blood donation (or corresponding blood loss) during the 3 months prior to screening.
- Investigator considers the subject unlikely to comply with study procedures, restrictions and requirements.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: C21
15 µg C21 (infusion rate 3 µg/min) 50 µg C21 (infusion rate 10 µg/min) 150 µg C21 (infusion rate 30 µg/min) 500 µg C21 (infusion rate 100 µg/min) 1000 µg C21 (infusion rate 200 µg/min)
|
C21 in ascending doses of 15, 50, 150, 500 and 1000 µg
Other Names:
|
Experimental: Control group
4 µg nitroprusside (infusion rate 0.8 µg/min) 8 µg nitroprusside (infusion rate 1.6 µg/min) 16 µg nitroprusside (infusion rate 3.2 µg/min)
|
Ascending doses of 4, 8 and 16 µg
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in forearm blood flow in response to increasing intraarterial doses of C21
Time Frame: 85 minutes
|
85 minutes
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Change from baseline in forearm blood flow in response to increasing intra arterial doses of sodium nitroprusside
Time Frame: 45 minutes
|
45 minutes
|
Frequency of adverse events
Time Frame: Day 7
|
Day 7
|
Intensity of adverse events
Time Frame: Day 7
|
Day 7
|
Seriousness of adverse events
Time Frame: Day 7
|
Day 7
|
Clinically significant changes in vital sign parameters
Time Frame: 5 hours
|
5 hours
|
Clinically significant changes in ECG parameters
Time Frame: 5 hours
|
5 hours
|
Clinically significant changes in safety laboratory parameters
Time Frame: 5 hours
|
5 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 28, 2022
Primary Completion (Actual)
May 11, 2022
Study Completion (Actual)
May 20, 2022
Study Registration Dates
First Submitted
March 3, 2022
First Submitted That Met QC Criteria
March 3, 2022
First Posted (Actual)
March 14, 2022
Study Record Updates
Last Update Posted (Actual)
November 14, 2022
Last Update Submitted That Met QC Criteria
November 11, 2022
Last Verified
November 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- VP-C21-009
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Study Vasodilatory Effects of C21
-
Lykos TherapeuticsCompletedPsychological Effects of Study DrugUnited States
-
Lykos TherapeuticsNot yet recruitingPsychological Effects of Study Drug
-
Dr Ulrik McCarthy PerssonCompletedFocus of Study is Effects of Neuromuscular TrainingIreland
-
Near East University, TurkeyCompletedTo Study the Effects of Protein Supplements on Blood TestsCyprus
-
Mark GlaisterNot yet recruitingThe Focus of the Study is to Investigate the Effects of Phosphatidylserine Supplementation on Exercise Physiology and Cycling Time-trial Performance
-
Hallym University Kangnam Sacred Heart HospitalCompletedIn the Present Study, we Investigated the Effects of Oral Ambroxol on Tear Film and Ocular Surface.Korea, Republic of
-
Linkoeping UniversityRyhov County HospitalCompletedFocus of StudySweden
-
Beijing Anzhen HospitalUnknown
-
King Saud UniversityUnknown
-
Gladwin, Mark, MDCompletedFocus of Study of Healthy AdultsUnited States
Clinical Trials on C21
-
Vicore Pharma ABOrphan ReachCompletedIdiopathic Pulmonary FibrosisUnited Kingdom, India, Ukraine, Russian Federation
-
Vicore Pharma ABCompletedCOVID-19Philippines, United States, Brazil, India, Russian Federation, Colombia, Argentina, Czechia, South Africa, Ukraine
-
Vicore Pharma ABOrphan ReachCompleted
-
Vicore Pharma ABCompletedEndothelial Dysfunction | Type2diabetesSweden
-
Vicore Pharma ABSGS Life Sciences, a division of SGS Belgium NVCompleted